VERTEX PHARMACEUTICALS INC / MA

VERTEX PHARMACEUTICALS INC / MA (VRTX) — Investment Memo

🐂 The Bull Case (Warren's voice)

We aren't buying a pharmacy; we are buying a toll bridge on the road to survival for thousands of people.

• The Unassailable Moat: Vertex doesn't compete on price; they compete on existence. In Cystic Fibrosis (CF), they have shifted from treating symptoms to correcting the underlying protein defect. When you own the only molecule that keeps a patient out of the hospital, your pricing power is absolute.
• Exceptional Economics:
  • High Conversion Rate: They've turned scientific curiosity into a $12.0B revenue engine. This isn't "spray and pray" R&D; it is surgical execution.
  • Captive Customer Base: Switching costs are effectively infinite. A patient stable on Trikafta does not "shop around" for a cheaper alternative.
  • Expansion optionality: The move into non-opioid pain management (VX-548) and CRISPR-based cures (Casgevy) represents a pivot from a single-disease company to a platform company.
• Attractive Entry: This becomes a Berkshire-grade investment when the market forgets that the CF moat is durable and prices it like a generic drug maker. If we can get this at a significant discount to its intrinsic value, we are buying a high-margin annuity with a growth kicker.

🐻 The Bear Case (Charlie inverts)

“Show me where I’ll die and I won't go there.” Let's look at the wreckage.

• The "Cure" Paradox: The ultimate risk is the success of their own logic. If a gene-editing therapy (like Casgevy) becomes a one-time "cure" rather than a lifelong "treatment," the recurring revenue model collapses. We trade a lifetime of annuity payments for a single, high-priced transaction.
• The Regulatory Guillotine: The US government is increasingly hostile toward "orphan drug" pricing. A structural shift in Medicare negotiation or a "price cap" on rare disease therapies would permanently impair the terminal value of the CF franchise.
• The Pipeline Cliff: Vertex is heavily concentrated. If the non-CF pipeline (Pain/Diabetes) fails to materialize or faces FDA rejection, the company becomes a "melting ice cube" as CF patents eventually expire.
• The 2024 Red Flag: That $0.5B net loss and $0.8B FCF hemorrhage in 2024 is a flashing neon sign. Whether it was a one-time impairment or a systemic blunder, it proves the business can be volatile and prone to massive, sudden write-downs.

💰 Valuation & Margin of Safety

Based on the provided DCF: $114.4B Total Value

• Intrinsic value estimate: $450.47 per share
• 25% margin of safety entry: $337.85 (Conservative)
• 50% margin of safety entry: $225.24 (Buffett's ideal)
• Current Status: Fairly valued to slightly expensive. If the stock is trading near $450, we are paying full price for a wonderful business, but we are not getting a "bargain." There is no margin for error at current levels.

Verdict: WATCH

The business is a scientific marvel with a dominant moat, but the current price offers no margin of safety. We wait for a market panic or a pipeline setback to drive the price toward $338. Conviction in the moat is high; conviction in the current price is low.